Arbutus Biopharma Corporation (ABUS) P/E Ratio History
Deep ValueTrading at -26.9x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2012–2026
Loading P/E history...
P/E Ratio Analysis
As of June 28, 2026, Arbutus Biopharma Corporation (ABUS) trades at a price-to-earnings ratio of -26.9x, with a stock price of $4.58 and trailing twelve-month earnings per share of $0.82.
The current P/E is 940% below its 5-year average of 3.2x. Over the past five years, ABUS's P/E has ranged from a low of 2.2x to a high of 5.5x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.0x, ABUS trades at a 217% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.4x.
Relative to the broader market, ABUS trades at a notable discount to the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ABUS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ABUS Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ABUS P/E vs Peers
RNA and Genome Editing Developers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $159B | 18.9 | 0.14Best | +1684%Best | |
| $39B | 125.1 | - | +207% | |
| $66B | 15.3Lowest | 2.41 | +8% | |
| $125B | 32.1 | 3.87 | +837% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ABUS Historical P/E Data (2012–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $4.50 | $0.82 | 5.5x | +70% |
| FY2013 Q3 | Sep 30 2013 | $6.95 | $1.90 | 3.7x | +14% |
| FY2013 Q2 | Jun 30 2013 | $4.70 | $2.06 | 2.3x | -29% |
| FY2013 Q1 | Mar 31 2013 | $4.71 | $2.12 | 2.2x | -31% |
| FY2012 Q4 | Dec 31 2012 | $4.96 | $2.05 | 2.4x | -25% |
Average P/E for displayed period: 3.2x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
14+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ABUS — Frequently Asked Questions
Quick answers to the most common questions about buying ABUS stock.
What is ABUS's P/E ratio?
Arbutus Biopharma Corporation (ABUS) trailing twelve-month P/E ratio is -26.9x, based on TTM diluted EPS of $0.82. The 5-year average P/E is 3.2x and the historical range spans 2.2x to 5.5x.
Is ABUS stock overvalued or undervalued?
ABUS trades at -26.9x P/E, below its 5-year average of 3.2x. At the 0th percentile of its historical range (2.2x–5.5x), the stock is priced at a discount to its own history.
Is ABUS stock expensive?
No, ABUS is not expensive on a historical basis. The current P/E of -26.9x is below the 5-year average of 3.2x and sits at the 0th percentile of its valuation range.
What is ABUS's historical P/E range?
Over the past 5 years, ABUS's P/E ratio has ranged from 2.2x to 5.5x, with a median of 2.4x and an average of 3.2x. The current P/E of -26.9x places the stock at the 0th percentile of this range. Full historical data spans 2012–2026.
How does ABUS's P/E compare to the S&P 500?
ABUS trades at -26.9x P/E versus the S&P 500 median of 25.3x. The 206% discount to the market suggests lower growth expectations or perceived higher risk.
How does ABUS's valuation compare to Healthcare peers?
Arbutus Biopharma Corporation P/E of -26.9x compares to the Healthcare sector median of 23.0x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ABUS's PEG ratio?
ABUS PEG ratio is N/A, based on a P/E of -26.9x and EPS growth of 55.3%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ABUS's earnings yield?
ABUS earnings yield is N/A, the inverse of its -26.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.